FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57198
News■ Unclear/unknown
Servier Adopts Veeva OpenData Globally to Scale AI
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 11:03 UTC
LAST UPDATE2026-09-30 11:03 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A pharma firm adopting AI-ready data infrastructure signals enterprise AI adoption in life sciences.
Pharma AI data adoption trend continues
CATALYST TO WATCH
Broader enterprise AI contract wins
MAIN RISK
Single customer deal, limited scale
FULL DISPATCH
Establishing an AI-ready data foundation in more than 80 countries PLEASANTON, Calif., Sept. 30, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Servier is standardizing customer reference data across more than 80 countries with Veeva OpenData. Building on its global...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDAI
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance2026-09-30 11:15 UTC
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance2026-09-30 11:15 UTC
→CORRELATIONshares AI
Cyngn Achieves ISO 27001 Certification, Strengthening Enterprise Security Readiness2026-09-30 11:15 UTC
Cyngn Achieves ISO 27001 Certification, Strengthening Enterprise Security Readiness2026-09-30 11:15 UTC
→CORRELATIONshares Healthcare
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.